Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 31;7(2):21.
doi: 10.3390/tropicalmed7020021.

Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa

Anja Reuter  1 , Buci Beko  1 , Boniwe Memani  1 , Jennifer Furin  2 , Johnny Daniels  1 , Erickmar Rodriguez  1 , Hermann Reuter  3 , Lize Weich  4 , Petros Isaakidis  5 , Erin von der Heyden  6 , Yulene Kock  7 , Erika Mohr-Holland  1   5
Affiliations

Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa

Anja Reuter et al. Trop Med Infect Dis. .

Abstract

Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was integrated into routine RR-TB care in Khayelitsha, South Africa. This was a retrospective study of persons with RR-TB who were screened for SU between 1 July 2018 and 30 September 2020 using the ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). Here we describe outcomes from this program. Persons scoring moderate/high risk received a brief intervention and referral to treatment. Overall, 333 persons were initiated on RR-TB treatment; 38% (n = 128) were screened for SU. Of those, 88% (n = 113/128) reported SU; 65% (n = 83/128) had moderate/high risk SU. Eighty percent (n = 103/128) reported alcohol use, of whom 52% (n = 54/103) reported moderate/high risk alcohol use. Seventy-seven persons were screened for SU within ≤2 months of RR-TB treatment initiation, of whom 69%, 12%, and 12% had outcomes of treatment success, loss to follow-up and death, respectively. Outcomes did not differ between persons with no/low risk and moderate/high risk SU or based on the receipt of naltrexone (p > 0.05). SU was common among persons with RR-TB; there is a need for interventions to address this co-morbidity as part of "person-centered care". Integrated, holistic care is needed at the community level to address unique challenges of persons with RR-TB and SU.

Keywords: ASSIST; RR-TB; SBIRT; brief intervention; integrated care; loss-to-follow-up; person-centered care; substance use.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Rifampicin-resistant tuberculosis substance-use intervention flow diagram (Screening, Brief Intervention and Referral to Treatment Model). This intervention could be implemented by doctors, nurses, or trainer lay counselors at primary health care facility.
Figure 2
Figure 2
Substance-use screening outcomes among persons initiated on RR-TB treatment from July 2018-September 2020. * TIK= crystal methamphetamines.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Global Tuberculosis Report 2021. [(accessed on 1 November 2021)]. Available online: https://www.who.int/publications/i/item/9789240037021.
    1. Ahmad N., Ahuja S.D., Akkerman O.W., Alffenaar J.C., Anderson L.F., Baghaei P., Bang D., Barry P.M., Bastos M.L., Behera D., et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Lancet. 2018;392:821–834. doi: 10.1016/S0140-6736(18)31644-1. - DOI - PMC - PubMed
    1. Law S., Daftary A., O’Donnell M., Padayatchi N., Calzavara L., Menzies D. Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: A systematic review. Eur. Respir. J. 2018;53:1801030. doi: 10.1183/13993003.01030-2018. - DOI - PubMed
    1. Shean K., Streicher E., Pieterson E., Symons G., van Zyl-Smit R., Theron G., Lehloenya R.J., Padanilam X., Wilcox P., Victor T.C., et al. Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. PLoS ONE. 2013;8:e63057. doi: 10.1371/annotation/644591a8-8ae6-450e-974e-1cd1f08f52c7. - DOI - PMC - PubMed
    1. Morris M.D., Quezada L., Bhat P., Moser K., Smith J., Perez H., Laniado-Laborin R., Estrada-Guzman J., Rodwell T.C. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: A patient’s perspective. Int. J. Tuberc. Lung Dis. 2013;17:954–960. doi: 10.5588/ijtld.12.0480. - DOI - PMC - PubMed

LinkOut - more resources